AUTHORS: Bois F, Noirot C, Dietemann S, Mainta IC, Zilli T, Garibotto V, and Walter MA
American Journal of Nuclear Medicine and Molecular Imaging, 10(6): 349-374, December 2020
ABSTRACT
Imaging of the prostate-specific membrane antigen (PSMA) has become an important tool for managing patients with recurrent prostate cancer, and one of the most frequently employed radiopharmaceuticals is [68Ga]Ga-PSMA-11. Herein, we summarize the preclinical development and the clinical applications of [68Ga]Ga-PSMA-11 and present side-by-side comparisons with other radiopharmaceuticals or imaging modalities, in order to assist imagers and clinicians in recommending, performing, and interpreting the results of [68Ga]Ga-PSMA-11 PET scans in patients with prostate cancer.
Download PDF
BibTex
Module: PET